MedTrace Logo

Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France

NCT02864758 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 99999

Last updated 2023-11-07

No results posted yet for this study

Summary

The purpose of the study is to compare the one-year and two-year risk of each of the following individual outcomes: Stroke and systemic embolism (SE), major bleeding and death between new users of anticoagulant for Stroke prevention in atrial fibrillation (SPAF) during drug exposure: rivaroxaban versus Vitamin K antagonists (VKA), and rivaroxaban versus dabigatran

Conditions

Interventions

DRUG

Rivaroxaban (Xarelto, BAY59-7939)

Tablets, 20mg once daily

DRUG

Vitamin K antagonists

Tablets, dose is based on International Normalized Ratio

DRUG

dabigatran (Pradaxa)

Tablets, 150 mg twice daily

Sponsors & Collaborators

  • Janssen Scientific Affairs, LLC

    collaborator INDUSTRY

  • Bayer

    lead INDUSTRY

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Min Age
2 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-08
Primary Completion
2018-09-30
Completion
2018-09-30

Countries

  • France

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02864758 on ClinicalTrials.gov